Does trimethoprim‑sulfamethoxazole (Bactrim) cause elevated lactate levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Bactrim Cause Elevated Lactate?

Yes, Bactrim (trimethoprim-sulfamethoxazole) can cause elevated lactate levels, though this is a rare but serious adverse effect primarily related to propylene glycol toxicity from the intravenous formulation.

Mechanism and Clinical Evidence

The intravenous formulation of Bactrim contains propylene glycol as a solvent, which is metabolized in the liver to lactic acid 1. While propylene glycol-induced lactic acidosis is well-recognized with high-dose lorazepam infusions, it can occur with TMP/SMX alone, even at allegedly safe doses of propylene glycol 1.

Key Clinical Case

A documented case involved a 31-year-old patient who developed severe lactic acidosis (lactate 12.1 mmol/L, pH 7.2) after only 3 days of intravenous TMP/SMX therapy 1. Critically:

  • The patient had normal hemodynamics and no hypotension or severe hypoxia
  • Renal and liver functions remained normal
  • Lactate normalized to 2.9 mmol/L within 24 hours of discontinuing TMP/SMX, without any other intervention
  • No alternative cause for lactic acidosis was identified 1

Clinical Context and Monitoring

This adverse effect is not listed in the FDA drug label 2, making it an underrecognized complication. The FDA label does mention other metabolic complications including:

  • Hyperkalemia (particularly with high doses)
  • Hyponatremia (especially in PCP treatment)
  • Hypoglycemia 2

High-Risk Scenarios

Propylene glycol-induced lactic acidosis with Bactrim is more likely when:

  • Using the intravenous formulation (oral formulations do not contain propylene glycol)
  • Treating Pneumocystis jirovecii pneumonia with high doses
  • Patients have impaired hepatic metabolism
  • Prolonged administration (though cases reported after just 3 days) 1

Practical Recommendations

Monitor for unexplained metabolic acidosis in patients receiving IV TMP/SMX:

  • Check lactate levels if unexplained tachypnea, altered mental status, or metabolic acidosis develops
  • Consider propylene glycol toxicity if anion gap metabolic acidosis occurs without other clear etiology
  • Discontinue TMP/SMX immediately if lactic acidosis is suspected—lactate should normalize within 24 hours if drug-related 1
  • Switch to oral formulation or alternative antibiotic if continued treatment needed

Important Caveat

While the Surviving Sepsis Campaign guidelines mention using lactate normalization to guide resuscitation in septic patients 3, clinicians must distinguish between lactate elevation from tissue hypoperfusion versus drug-induced lactic acidosis. In the latter, the patient typically lacks other signs of shock (normal blood pressure, adequate urine output, no organ dysfunction) 1.

Bottom line: Suspect TMP/SMX-induced lactic acidosis when a patient on IV Bactrim develops unexplained metabolic acidosis with elevated lactate but maintains hemodynamic stability and normal organ function. Immediate drug cessation is both diagnostic and therapeutic.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.